The urokinase plasminogen activator (uPA) system is among the most crucial pericellular proteolytic systems associated with the processes of angiogenesis. We previously identified an important regulator of the uPA system in the mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R).
D uring tumor-associated angiogenesis, pericellular proteolytic systems are indispensable for endothelial cells to degrade surrounding matrix and sprout into new blood vessels. Similar machineries are hired by metastatic cells to invade tissues. Therefore, understanding of how these forces are regulated is crucial in recognizing new targets and establishing novel strategies for antiangiogenesis and anticancer therapy. 1 The urokinase plasminogen activator (uPA) system is well known to mediate cell surface proteolysis in both endothelial and cancer cells. 2 After binding to the uPA receptor (uPAR, CD87), inactive single-chain pro-urokinase is processed to double-chain urokinase (uPA), the central plasminogen (Plg) activator on the cell surface. The active serine protease plasmin facilitates breakdown of extracellular matrix components both directly and through the activation of matrix metalloproteinases (MMP). 3 Vascular endothelial growth factor (VEGF), a pivotal proangiogenic factor induces activation of pro-urokinase and redistribution of uPAR to the leading edge of migrating endothelial cells. 4 Moreover, uPAR is located in the leading edge of invading cancer cells. 5 Thus, the uPA system plays a key role in tumor progression and specific targeting of this system has been recognized as a promising approach to treat cancer diseases. 6 We have previously shown that the mannose 6-phosphate/ insulin-like growth factor 2 receptor (M6P/IGF2R, CD222) inhibits uPAR functions in cell surface proteolysis and cell migration. 7 Furthermore, we have proposed a mechanism whereby membrane-associated M6P/IGF2R controls cell invasion by regulating ␣V integrin expression and by accelerating uPAR cleavage leading to loss of the uPA-binding site on uPAR. 8 Here, we put forward one more pathway through which M6P/IGF2R contributes to inhibition of the uPA system. The tumor necrosis factor ␣ convertase (TACE, ADAM17) mediates the release of the ectodomain of M6P/ IGF2R. This soluble form (sM6P/IGF2R) binds to Plg and, through blocking the interaction between Plg and uPA, ultimately inhibits pericellular Plg activation. We show further that a peptide derived from the Plg-binding site of M6P/IGF2R mimics sM6P/IGF2R in the inhibition of Plg activation and blocks cancer cell invasion in vitro, endothelial cell invasion in vivo and tumor growth in vivo.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
RNA Interference
To silence the expression of TACE, we transiently transfected primary human umbilical vein endothelial cells (HUVECs) with small interfering (si)RNA according to the instructions of the manufacturer.
Immunobiochemical Techniques
SDS-PAGE, immunoblotting, blue native electrophoresis (BN-PAGE), protein purification, gel filtration, in vitro binding, immunoprecipitation, and plasmin activity assays were performed as described previously with some modifications.
In Vitro and In Vivo Assays
Cell invasion, in vitro endothelial cell tube formation, in vivo angiogenesis Matrigel plug assays, and the chimeric human/mouse tumor model were all performed as previously described.
Results
The Release of sM6P/IGF2R Is Mediated by TACE M6P/IGF2R was shown to be released by hepatocytes and tumor cells 9,10 ; here, we found that M6P/IGF2R was released also by HUVECs. HUVECs were grown to confluent monolayers and then cultured for 24 hours under serum-free conditions. The soluble receptor was detectable in the supernatant after 3 hours and accumulated further ( Figure 1A ). The size of sM6P/IGF2R was Ϸ220 kDa indicating that the whole ectodomain was released. This was in accordance with previously described soluble forms of M6P/IGF2R. 11, 12 Shorter fragments were not detected. We confirmed the specificity of the band by checking the supernatants derived from immortalized human endothelial cells (HUVECtert 8 ) with normal and silenced expression of M6P/IGF2R (Online Figure I) . We also observed the 220 kDa sM6P/IGF2R in the supernatants of human smooth muscle cells, the human kidney carcinoma cell line TCL-598, the human T-cell lymphoblast-like cell line Jurkat and the human monocytic cell line THP-1 (data not shown).
We tested various protease inhibitors for their ability to block the release of sM6P/IGF2R and found that the broad MMP inhibitor GM6001 (galardin), the TACE inhibitor TAPI and the MMP-8 inhibitor I blocked the shedding completely ( Figure 1B and 1E ). Shedding was partially blocked by the MMP-3 inhibitor II; however, this was attributable to its toxic effect on HUVECs. Because the inhibitors are relatively nonspecific, we expressed in HUVECs siRNA constructs targeting 2 messenger RNA regions of TACE. Transfection of HUVECs with one of the 2 TACE-specific siRNAs (TACE 2 ) resulted in a significant reduction of TACE expression and this downregulation correlated significantly with the reduced release of sM6P/IGF2R ( Figure 1C and 1E). We did not detect any expression of MMP-8 at the protein level by immunoblotting analysis (data not shown). Regardless, we performed the silencing procedure of MMP-8 that, expectedly, had no effect on shedding. Notably, an unspecific inhibition of the TACE-mediated shedding by MMP-8 inhibitor I was already reported also by others. 13 As a further proof of the involvement of TACE in the shedding of sM6P/IGF2R, we tested also the supernatants of wild type and TACE Ϫ/Ϫ mouse embryonic fibroblasts for the presence of sM6P/ IGF2R. In wild type cells, the shedding was again reduced by GM6001. As expected, in TACE Ϫ/Ϫ cells, the release of sM6P/IGF2R was significantly, but not completely, reduced (Ϸ80% reduction) ( Figure 1D and 1E). These results provide strong evidence that TACE is involved in the proteolytic release of the M6P/IGF2R ectodomain; however, a possible contribution from other mechanisms cannot be excluded.
Interactions of sM6P/IGF2R With Plg
Although there are several studies demonstrating soluble forms of M6P/IGF2R in the circulation of rat and human, 14 -16 the function of sM6P/IGF2R has not been resolved. We characterized previously the membrane form of cellular M6P/IGF2R as a receptor for Plg. 7, 17 Because Plg is an abundant serum protein, 18 we asked whether sM6P/IGF2R might bind serum Plg too and affect its function. To explore this possible functional association, we attempted to coimmunoprecipitate these 2 proteins from human serum. It was reported that the level of sM6P/IGF2R in rat serum increased on liver damage. 12, 19 Similarly, we found increased levels of sM6P/IGF2R in sera from patients with various liver disorders (Online Figure II) , and we used these serum samples for our study.
We coprecipitated serum Plg with the anti-M6P/IGF2R monoclonal antibody (mAb) MEM-240; and vice versa, we coprecipitated sM6P/IGF2R with the anti-Plg mAb 4Pg ( Figure 2A ). MEM-240 recognizes an epitope within the extracellular repeat domains 6 to 9 of M6P/IGF2R 7 ; 4Pg recognizes an epitope within the catalytic part of Plg. 20 In contrast, the mAbs MEM-238 and 7Pg, recognizing an epitope within the amino-terminal region of M6P/IGF2R 7 and the kringle 4 of Plg 20 respectively, were less efficient; however, both recognized the precipitated material on the immunoblot indicating that the corresponding epitopes were hidden within the complex and not released or destroyed, which was in line with a recently published study. 21 We scrutinized the Plg-sM6P/IGF2R complex in serum by BN-PAGE, which allowed a complex dissection by the Leksa et al Soluble M6P/IGF2R Inhibits Plasminogen Activation separation of native protein complexes in the first dimension followed by SDS-PAGE in the second dimension. We found that Plg and sM6P/IGF2R were mainly cocomplexed in a high-molecular-weight complex of more than 880 kDa and a complex of approximately 500 kDa. The majority of Plg was apparently smaller than 272 kDa ( Figure 2B ). We complemented these data with another approach; we fractionated the serum sample by gel filtration through Superose 6 column. In doing so we isolated 3 groups of fractions similar to those identified by BN-PAGE: a high molecular weight complex (Ն2000 kDa; fractions 5, 6 eluted in the void volume of the column), an intermediate molecular weight complex (Ϸ600 kDa; fractions 15, 16) , and low molecular weight fractions (Ϸ90kD; fractions 22 to 26). The high and intermediate molecular weight complexes contained sM6P/IGF2R in addition to Plg, likewise in BN-PAGE. The low molecular weight fraction corresponded to the size of the single Plg molecule and was free of sM6P/IGF2R ( Figure 2C ). To evaluate the responsiveness of these different serum Plg forms to the activation by uPA, the representative fractions (6, 15, 24) were standardized to the same Plg concentration and subjected to an activation assay with uPA. The com-plexed forms were activated to a lesser extent when compared to the low molecular weight form of Plg ( Figure 2D ). In contrast, the purchased purified Plg was detected only in the low molecular weight fractions (data not shown). Thus, Plg is present in serum in different forms and the complexed Plg-sM6P/IGF2R molecules seem to be less susceptible to uPA activation than the single Plg molecule. Next, an in vitro binding assay showed that the direct interaction of sM6P/IGF2R with Plg, very recently verified also by others, 21 was not blocked by the known ligands of M6P/IGF2R including M6P, latent transforming growth factor (LTGF)␤, IGF2 and retinoic acid ( Figure 2E ). This finding is in agreement with the binding site for Plg mapped within the amino-terminal part of domain 1 of M6P/ IGF2R. 7, 22, 23 This site is distinct from the binding sites for the other ligands including M6P (domains 3, 5, 9), 24 IGF2 (domain 11) 25, 26 or retinoic acid (probably in the cytoplasmic domain). 27 Furthermore, the peptide derived from this aminoterminal Plg-binding region, termed peptide 18-36, 7,22 but not the scrambled peptide reduced the in vitro binding of sM6P/ IGF2R to Plg by Ϸ55Ϯ10% (nϭ4; Figure 2E ). This result has proven that sM6P/IGF2R, alike the full-length membrane form of M6P/IGF2R, binds Plg through the amino-terminal part of domain 1. Finally, various shorter soluble forms occur in serum and conditioned media probably representing proteolytic fragments of sM6P/IGF2R. 10, 28 We tested whether plasmin per se could be responsible for the fragmentation of sM6P/IGF2R. Indeed, when we subjected purified M6P/IGF2R to in vitro proteolysis, plasmin but not uPA enabled its proteolytic processing (Online Figure III) . These data indicate that a proteolytic processing of M6P/IGF2R may yield shorter soluble fragments. Notably, we also precipitated a shorter form (Ϸ50 kDa) from serum (Figure 2A ). It is feasible that the shorter sM6P/IGF2R fragments which still convey the Plg-binding site might be able to bind Plg and be of functional relevance.
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sM6P/IGF2R and Peptide 18-36 Have a Similar Negative Regulatory Effect on Plg Activation
Plg binding to the cell surface is a prerequisite for its controlled activation. 29 Based on this assumption and the data presented above, it was conceivable that sM6P/IGF2R could be affecting Plg activation; and that peptide 18-36, derived from the Plg-binding region of M6P/IGF2R, could be a suitable modulatory tool to test this hypothesis. Therefore, we Precipitates were analyzed by immunoblotting (IB) using anti-Plg mAb 7Pg and goat polyclonal anti-M6P/IGF2R Ab and chemiluminescence for development. B, Human serum sample was diluted 10 times with PBS and analyzed by BN-PAGE in the first dimension followed by SDS-PAGE in the second dimension as described in Methods. Coomassie brilliant blue (CBB) stained ferritin (monomer 440 kDa, dimer 880 kDa) and jack bean urease (monomer 91 kDa, trimer 272 kDa, hexamer 545 kDa) were used in the first dimension as molecular weight markers. For the immunoblotting analysis of the second dimension gel, the reactivity of the M6P/IGF2R mAb MEM-238 and the Plg mAb 7Pg was developed by HRP conjugation and chemiluminescence. C, Human serum sample was diluted 1:1 with PBS and fractionated by gel filtration through Superose 6 column. The fractions were analyzed by immunoblotting using the anti-M6P/IGF2R mAb MEM-238, anti-Plg mAb 7Pg, and rabbit polyclonal antiplasmin Ab. Molecular weight standards are specified in Methods. D, Representative fractions 6, 15, and 24 standardized to the same concentration (5 g/mL) were subjected to an activation assay in wells coated with uPA together with the chromogenic plasmin substrate S-2251 (0.8 mmol/mL). After 6 hours, the absorbance change at 405 nm was monitored. *PϽ0.05, **PϽ0.005 as indicated (nϭ3). In A through D, similar results were obtained, with several nutritional-toxic liver cirrhosis patient serum samples containing high concentrations of sM6P/IGF2R (Online Figure II) . E, Plg was coated on wells of a 96-well plate. The wells were then incubated with purified sM6P/IGF2R (40 g/mL) in the absence or presence of M1P, M6P, LTGF␤, IGF2, retinoic acid (RA), peptide 18-36 (pep18-36) or scrambled peptide (pepSCR). Bound material was analyzed as in A.
Leksa et al
Soluble M6P/IGF2R Inhibits Plasminogen Activation analyzed both sM6P/IGF2R and peptide 18-36 for their ability to influence Plg function. We found that sM6P/IGF2R blocked the binding of Plg to the cell surface similarly to the lysine analog tranexamic acid (TA), an inhibitor of lysine-dependent binding of Plg to its receptors, by Ϸ60%. Peptide 18-36 blocked the cell surface binding by 45% compared to scrambled peptide ( Figure 3A ). Because it had been shown before that a direct interaction between uPA and Plg was necessary for Plg activation on the cell surface, 30, 31 we tested whether sM6P/IGF2R and peptide 18-36 were able to block this interaction. An in vitro binding assay revealed that similarly to TA, sM6P/IGF2R and peptide 18-36 both blocked the interaction between Plg and uPA ( Figure 3B ). The efficient blocking concentration for sM6P/ IGF2R was 40 g/mL (Ϸ200 nmol/L); for peptide 18-36 it was 2.5 g/mL (Ϸ1 mol/L). In parallel, we performed a Plg activation assay in a cell-free system on uPA-coated plastic wells. We found that both sM6P/IGF2R and peptide 18-36 inhibited Plg activation ( Figure 3C) . In contrast to the Plg activation assay, in the binding assay peptide 18-36 blocked at the lower concentration (compare Figure 3B and 3C) , which could be attributable to the higher stringency condition in the binding assay. These data suggest that sM6P/IGF2R exerts its negative regulatory functions in Plg activation via preventing Plg from its binding to uPA, and peptide 18-36, derived from the Plg-binding site of M6P/IGF2R, can mimic sM6P/IGF2R in this activity.
Modulation of Angiogenesis and Tumor Growth by sM6P/IGF2R and the M6P/IGF2R-Derived Peptide 18-36
Given that both endothelial and tumor cells use the uPA/Plg system to invade tissues during angiogenesis 6 and tumor pro- Plasmin activity (OD405 nm) gression, 2 we tested whether sM6P/IGF2R as well as the sM6P/IGF2R-mimicking peptide 18-36 could modulate these processes. First, we tested sM6P/IGF2R and peptide 18-36 in an angiogenesis assay in vitro. We seeded primary HUVECs on Matrigel, whereon they form a tube-like network. The total tube length of the cells grown on Matrigel preincubated with peptide 18-36 at the final concentration of 20 g/mL was reduced by 61% (Pϭ1ϫ10 Ϫ4 ). A similar effect we observed with the cells treated with sM6P/IGF2R (46% and 67% reduction with 20 and 40 g/mL, respectively), in contrast to the cells incubated without these substances or scrambled peptide. Notably, aprotinin, MMP-2/MMP-9 inhibitor, or the TACE inhibitor TAPI blocked the tube network formation ( Figure 4A and 4B ). Next, we performed a tube formation with TACE-silenced HUVECs in the presence or absence of sM6P/IGF2R and peptide 18-36. The siRNA-mediated silencing of TACE resulted in a reduction of the total tube length by Ϸ30% when compared to control cells, which is in line with published data. 32, 33 Addition of sM6P/IGF2R or peptide 18-36 to TACE-silenced cells resulted in a further inhibition by 27% and 37%, respectively; similarly to control cells (28% and 53%, respectively; Online Figure IV, A and B) . We also tested immortalized HUVECtert with and without silenced expression of M6P/IGF2R 8 for their ability to form tubes in the same assay. In comparison to the primary HUVECs, HUVECtert formed a less developed tube-like network that might be attributed to the higher expression of M6P/IGF2R on the surface of these immortalized cells (data not shown). However, on M6P/IGF2R silencing the tube formation was forwarded by 35% (Pϭ0.04), again supporting the regulatory role of M6P/IGF2R in angiogenesis (Online Figure IV, C and D) .
The strong antiangiogenic effect of peptide 18-36 in the in vitro tube formation assay suggested a pharmacological potential of this substance. Therefore we tested peptide 18-36 further in in vivo models in mice:
First, we generated mouse analogues of peptide 18-36 (peptide 22-40m); the corresponding sequence is highly conserved between the species (Online Figure V) . Next, we analyzed its ability to inhibit the formation of vessel-like structures in an in vivo angiogenesis model by using a murine Matrigel plug assay. Peptide 22-40m or control peptide was mixed into Matrigel solution in the presence of VEGF (10 nmol/L). These mixtures were injected subcutaneously into mice and analyzed 5 days thereafter. In the presence of scrambled peptide, CD31 ϩ endothelial cells massively invaded the plugs and formed vessel-like structures ( Figure  4C) . In contrast, when we mixed peptide 22-40m into Matrigel, we observed significantly reduced endothelial cell numbers within the plugs (64% reduction; Pϭ8ϫ10 Ϫ10 ) and nearly no vessel-like structures. Instead, CD31 ϩ endothelial cells stayed confined on the rim of the Matrigel (Figure 4C  and 4D) . Functionality of the vessel-like structures in the control plugs was manifested by the presence of Ter119 ϩ erythrocytes, whereas no erythrocytes were detected in the plugs when peptide 22-40m was incorporated (data not shown). Moreover, peptide 22-40m reduced significantly the total cell number in the plugs (40% reduction; Pϭ2.75ϫ10 Ϫ3 ) indicating that peptide 22-40m affected the invasion of other cells as well. To identify the type of these cells we stained the plugs with mAbs against various markers and found that CD11b ϩ cells were significantly reduced in the plugs with peptide 22-40m (44% reduction, Pϭ2.70ϫ10 Ϫ4 ). In contrast, we did not observe significant differences with markers for granulocytes, monocytes and macrophages (Gr-1, MoMa-2 and F4 -80) ( Figure 4D ). In addition, we did not detect positive cells within the plugs by using mAbs against CD3 (the marker for T cells), CD45RB (B cells) and NK1.1 (natural killer cells). Based on these findings, we assume that the CD11b ϩ cells could be a subset of dendritic cells. Strikingly, dendritic cells have been shown to play an important role in regulation of angiogenesis 34, 35 and, similarly to endothelial cells, do use the uPA/Plg system to migrate. 36 Second, we studied the effect of peptide 18 -36 on tumor growth in a chimeric in vivo model by growing human melanoma cells in SCID mice: the human melanoma M24met cells were injected into the right flank of an animal and at the same time an osmotic pump filled with either scrambled peptide or peptide 18-36 was implanted at a distal position in the same flank. Tumor size was measured daily. After 14 days, peptide 18-36 inhibited significantly the tumor growth (Ϸ50% reduction; Pϭ0.02; nϭ4; Figure 4E ). Then we went back to a pure human system and tested the potential modulatory role of peptide 18-36 on cell invasion in a tumor cell invasion model based on basement membrane and Matrigel in a Boyden chamber set-up. Peptide 18-36 significantly inhibited FCS/EGF-induced invasion of the human kidney carcinoma TCL-598 cells ( Figure 4F ). Importantly, peptide 18-36 inhibited cell invasion to the same extent as the broad MMP inhibitor galardin (GM6001) or the uPA inhibitor amiloride. The relative effects of the peptide on tumor endothelial cells versus tumor cells in vivo remain to be investigated in future.
Discussion
M6P/IGF2R is expressed ubiquitously in a majority of higher eukaryotic cell types. Cellular M6P/IGF2R is known to possess variegated binding capacity and be involved in manifold physiological functions. 37, 38 The physiological role of its soluble form has not been clearly resolved yet. A task in transporting and neutralization of IGF2 was suggested. 39 -41 However, a reduction of organ size by sM6P/IGF2R was observed also independent of the IGF2 neutralization. 42 Furthermore, a role in transporting lysosomal enzymes was discussed. 43 In addition, M6P/IGF2R is known to bind a variety of ligands present in serum such as LTGF␤, 44 heparanase, 45 leukemia inhibitory factor, 46 or Plg. 7 Based on the results presented here, we suggest that sM6P/ IGF2R inhibits Plg activation through preventing Plg from binding to uPA and in this manner modulates cell invasion. This regulatory mechanism of sM6P/IGF2R seems to be different from the inhibitory effect mediated by plasminogen activator inhibitor (PAI)-1, which involves internalization of the uPA-uPAR complex. 47 The difference is indicated by several data. First, sM6P/IGF2R and PAI-1 exhibit additive inhibitory effects on Plg activation (Online Figure VI) . Second, PAI-1 inhibited Plg activation even in the absence of cellular M6P/IGF2R. 7, 8 Leksa et al Soluble M6P/IGF2R Inhibits Plasminogen Activation supplemented with VEGF (10 nmol/L) and the indicated peptides (20 g/mL) were injected subcutaneously. After 5 days, mice were euthanized and the Matrigel plugs were removed, fixed in 4% paraformaldehyde, embedded in paraffin, and stained. The samples were analyzed with an Olympus AX70 microscope. Digital images were taken by an F-view camera. D, Numbers of cells in Matrigel plugs from C were quantified on images displaying sections of the complete plugs. The images were divided into 1-mm 2 segments, and the number of cells within each segment was counted. Data from a representative experiment are shown. Similar results were obtained Third, neither cellular M6P/IGF2R nor a peptide derived from M6P/IGF2R affected uPAR internalization. 4, 8 The release of M6P/IGF2R from the cell, detected in the past, seemed to occur by cell surface proteolysis 9, 11, 16, 48 ; however, an alternative nonproteolytic pathway was proposed as well. 12 Here we show that TACE/ADAM-17 mediates shedding of M6P/IGF2R; though our data do not exclude contributions of other mechanisms. ADAM family proteases have crucial roles in angiogenesis and cancer biology 49 ; in particular, TACE was suggested to be proangiogenic through MMP-2 activation 32 and also to be involved in pathological neovascularization. 33 Our data indicate that TACE contributes also to a negative regulation of angiogenesis through the release of M6P/IGF2R that downregulates Plg activation. Interestingly, plasmin itself can contribute to the activation of MMP-2. 3 Because TACE can cleave a wide array of plasma membrane proteins, 50, 51 it is reasonable to speculate that the TACE-mediated regulation of angiogenesis depends on the receptor milieu. Whether TACE-mediated shedding is the major source of sM6P/IGF2R in vivo and how this mechanism contributes to the regulation of angiogenesis at the physiological or pathological level should be clarified in future studies. Because a conventional whole body knockout of TACE is neonatally lethal, 52 inducible conditional knockouts will be highly useful for these studies.
By BN-PAGE and gel filtration we found sM6P/IGF2R to be complexed with a fraction of Plg. Plg is present in serum at a concentration of Ϸ2 mol/L 18 . We detected different serum sM6P/IGF2R-Plg complexes. Namely, we found Plg and sM6P/IGF2R in an apparently high-molecular weight complex and also a complex of intermediate molecular weight. On the other hand, the majority of Plg was present in smaller forms corresponding to the size of the single Plg molecule (Figure 2 ). A precise composition and functionality of these complexes need to be solved in future. Interestingly, the binding of Plg to the plasma histidine-rich glycoprotein was found to enhance its activation 53 ; in contrast, our data indicate that the serum Plg complexed with sM6P/IGF2R is less responsive to the activation by uPA than the single Plg molecule.
sM6P/IGF2R appears to block Plg activation at a concentration of 200 nmol/L (Figure 3) , ie, with similar affinity as M6P/IGF2R binds to Plg. 21, 22 In healthy donors, we measured the concentration of sM6P/IGF2R to be 6 g/mL (Ϯ1 g/mL; nϭ6) corresponding to Ϸ27 nmol/L (Online Figure  II) , which was to some extent higher than the 3 to 4 nmol/L reported previously for healthy adult humans. 16 This difference could be caused by different capabilities of various mAbs to bind and detect differentially truncated sM6P/ IGF2R. In fact, the values of sM6P/IGF2R measured by specific immunoassays might be underrated because they most likely related to the whole ectodomain. Shorter fragments, which were also detected in serum (Figure 2A) , 10, 28 could escape a standard ELISA-or Western blotting-based measurement by the lack of antibody recognition. Such fragments could be produced by proteolytic degradation, for example mediated by plasmin (Online Figure III) , and may presumably have similar functional properties as sM6P/ IGF2R, on the condition that they still retain the Plg-binding region. This is reasonable because plasmin has a natural affinity to cleave proteins at lysine residues 54 and there are several lysines within the amino-terminal Plg-binding part of sM6P/IGF2R (Online Figure V) . The processing of Plg receptors by plasmin is a well-characterized pathway to upregulate Plg binding to cells via C-terminal lysines. 29 Therefore, one can speculate that not only new Plg-binding sites are generated on the cell surface in this way but also soluble peptides capable of modulating Plg function.
The serum concentration of sM6P/IGF2R may be regulated developmentally or altered during certain disorders. 16 We show here that the serum concentration of sM6P/IGF2R dramatically increases in liver cirrhosis patients (Online Figure II) . It is known that there are many changes in the fibrinolytic system accompanying severe hepatic disease, which may affect fibrinolytic balance. 55, 56 Whether the increased level of sM6P/IGF2R is associated with the increased tendency to develop thromboses in patients with cirrhosis must be evaluated in future. High concentrations of sM6P/ IGF2R might be reached in certain environmental conditions such as cell-cell or cell-matrix contact zones in the bargain. The interaction of sM6P/IGF2R with Plg may be of considerable regulatory importance within the microenvironment of migrating cells in which the uPA/uPAR complex is localized in leading edges 5 to activate cell-surface Plg. 30, 31 One could also speculate that secreted sM6P/IGF2R may through its properties contribute to tumor-suppressive senescence mechanisms attributed to M6P/IGF2R. 57 Finally, peptide 18-36 that is derived from the Plg binding site within the amino-terminal region of M6P/IGF2R 7,23 does possess a modulatory capability in angiogenesis and tumor growth ( Figure 4 ). This property of peptide 18-36 may result from its inhibitory effect on uPA-Plg binding and Plg activation (Figure 3) . Thus, the migration and growth of cell types harnessing the Plg system should be specifically blocked by peptide 18-36, as actually demonstrated for endothelial cells, CD11b ϩ cells (putative dendritic cells), and The number of endothelial cells was measured by staining with a CD31 mAb, and the total cell number was evaluated by DAPI staining. In addition, granulocytes were evaluated by staining with mAb Gr-1, monocytes by mAbs MoMa-2 and F4 -80, CD11b ϩ cells (monocytes, macrophages, dendritic cells) by CD11b mAb. *PϽ0.05, **PϽ0.005, ***PϽ0.0005 as indicated (meanϮSD; nϾ14). E, To study the effect of peptide 18-36 on tumor growth in vivo, the human melanoma M24met cells were injected into the right flank of pathogen-free 6-week-old female CB17 SCID mice. At the same time, osmotic pumps filled with either scrambled peptide or peptide 18-36 were implanted at a distal position in the same flank. Tumor size was measured daily during the 15 days of treatment. *PϽ0.05, **PϽ0.005 as indicated (meanϮSEM; nϭ4). F, Effect of peptide 18-36 on tumor cell invasion was tested by using a modified Boyden chamber coated with basement membrane and Matrigel. The Matrigel was preincubated with the peptides (20 g/mL) or the indicated inhibitors in FCS-free RPMI-1640 for 1 hour at 37°C. Then, human kidney carcinoma TCL-598 cells were seeded on top of the filter and incubated for 18 hours at 37°C. EGF (10 ng/mL) in RPMI-1640 plus 10% FCS was used as chemoattractant in the bottom chamber. The concentrations of the used inhibitors were: galardin/GM6001 (GM) (10 mol/L), amiloride (10 mol/L), pepstatin A (10 mol/L), and E-64 (10 mol/L). Results are representative for 3 independent experiments. *PϽ0.05, **PϽ0.005 as indicated (nϭ3). tumor cells ( Figure 4 ). Using this peptide for pharmacological downregulation of the Plg activation system may represent a novel therapeutic approach that would inhibit tumorassociated angiogenesis and tumor progression.
Novelty and Significance
What Is Known?
• Pericellular proteolytic systems, such as the urokinase plasminogen activator (uPA)/plasmin system, are essential for cells that have to migrate to execute their functions (for instance, immune cells to target pathogens or endothelial cells to form vessels). However, malignant cells hijack them for invasion and metastasis. • The transmembrane mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R, CD222) is an important regulator of the uPA system. • The tumor necrosis factor ␣ convertase (TACE, ADAM-17) is involved in the proteolytic release of various membrane proteins in the process also known as "shedding."
What New Information Does This Article Contribute?
• TACE mediates the release of the ectodomain of M6P/IGF2R (soluble M6P/IGF2R) from human endothelial cells. • The levels of sM6P/IGF2R are elevated in sera of liver disease patients. • sM6P/IGF2R binds plasminogen (Plg) and thereby prevents Plg from binding to the cell surface and uPA, ultimately inhibiting in this manner Plg activation to active plasmin. • Peptide 18-36 derived from the Plg-binding site of M6P/IGF2R mimics sM6P/IGF2R in the inhibition of Plg activation, and blocks cancer cell invasion in vitro, endothelial cell invasion in vivo and tumor growth in vivo.
Cell movement is required for several physiological processes; however, rampant cell migration is a hallmark of tumor cell dissemination and tumor-associated angiogenesis. Cell migration engages several processes including cell adhesion, pericellular proteolysis, and cytoskeletal rearrangements. The cellassociated uPA system results in the generation of the potent serine protease plasmin and is therefore essential for the proteolytic breakdown of extracellular matrix proteins within tissue barriers. Thus, the uPA system plays a key role in tumor progression and specific targeting of this system has been recognized as a promising approach to treat carcinogenesis.
Here, we show that sM6P/IGF2R inhibits pericellular Plg activation by blocking the interaction between Plg and uPA. In view of these observations it is possible that elevated concentrations of sM6P/IGF2R in sera of liver cirrhosis patients might contribute to deregulation of fibrinolysis accompanying this disorder. Our observation that the release of sM6P/IGF2R is mediated by TACE adds a new facet to the role of this sheddase in regulating angiogenesis and tumor progression. Our results showing that peptide 18-36 derived from the Plg-binding site of M6P/IGF2R mimics sM6P/IGF2R in the inhibition of Plg activation suggest that the use of this peptide may represent a potential therapeutic tool for modulating cell migration.
